Evidence map›Paper›PMID 41065822›Full record

ArticleActa neuropathologica2025

Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells.

Catharina Lotsch, Rolf Warta, Fang Liu, Gerhard Jungwirth, Carmen Rommel, Mandy Barthel, Katrin Lamszus, Almuth F Kessler, Niels Grabe, Mario Loehr and 12 more

Abstract read
In one paragraph

Article in Acta neuropathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Catharina Lotsch *Division of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Rolf Warta *Division of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Fang Liu *Division of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Gerhard JungwirthDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Carmen RommelDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Mandy BarthelDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Katrin LamszusDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Almuth F KesslerDepartment of Neurosurgery, University Hospital Würzburg, Würzburg, Germany.
Niels GrabeHamamatsu Tissue Imaging and Analysis Center (TIGA), BIOQUANT, Heidelberg University, Heidelberg, Germany.
Mario LoehrDepartment of Neurosurgery, University Hospital Würzburg, Würzburg, Germany.
Ralf KetterDepartment of Neurosurgery, Saarland University, Medical School, Homburg, Germany.
Christian SenftDepartment of Neurosurgery, University of Jena, Jena, Germany.
Sybren L N MaasDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Philipp SieversClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Manfred WestphalDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sandro M KriegDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Andreas UnterbergDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Matthias SimonDepartment of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Andreas von DeimlingClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Felix SahmClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
David R RaleighDepartments of Radiation Oncology, Neurological Surgery, and Pathology, University of California San Francisco, San Francisco, CA, USA.
Christel Herold-MendeDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. H.Mende@med.uni-heidelberg.de.

Funding

Deutsche Krebshilfe 70112956Medizinischen Fakultät Heidelberg, Universität Heidelberg Physician Scientist Program
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) represent the main immune cell population in various brain malignancies, but there is rare knowledge on the functional and, in particular, the prognostic role of TAMs in the meningioma (MGM) microenvironment. Here, we investigated TAM frequencies, activation state, survival-associated changes, and their association with tumor-infiltrating T lymphocytes (TILs) in two independent study samples comprising altogether 680 MGMs. To this end, we performed tissue cytometry analyses, quantified tissue cytokine levels, and integrated previously published TIL infiltration and microarray datasets in the discovery cohort comprising n = 195 clinically well-annotated cases. This was complemented by a DNA methylation-based deconvolution approach to predict TAM and TIL infiltration rates using immune cell-specific CpG sites as well as survival associations in an independent validation cohort of n = 485 MGMs. Our findings revealed substantial but heterogeneous TAM infiltration in newly diagnosed MGMs, with increased numbers of pro-tumoral TAMs in clinically aggressive tumors. Additional cytokine and transcriptome analyses corroborated the presence of an immunosuppressive niche in TAM-enriched MGMs. Importantly, a high frequency of pro-tumoral TAMs was associated with poor patient outcome, and high TAM infiltration was further identified as an independent prognostic factor for inferior survival, counteracting the beneficial prognostic effect of TILs. Moreover, methylation-based deconvolution analyses confirmed the opposing prognostic roles of TAMs and TILs in the validation cohort. Altogether, higher numbers of TAMs appear to be a hallmark of clinically aggressive behavior in newly diagnosed and recurrent MGMs. Unlike TILs, immunosuppressive TAMs seem to play a dominant role in the immunological landscape of MGMs with a significant negative impact on patient outcome, highlighting pro-tumoral TAMs to be an attractive treatment target in MGMs. Furthermore, our deconvolution approach presents a pipeline to computationally determine TAM and TIL infiltrates in the MGM microenvironment, which might be highly valuable for patient stratification for future immunotherapeutic treatments.

Indexed as

Lymphocytes, Tumor-InfiltratingMeningeal NeoplasmsMeningiomaT-LymphocytesTumor-Associated MacrophagesAdultAgedBiomarkers, TumorDNA MethylationFemaleHumansMaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorDeconvolutionDNA methylationMacrophagesMeningiomaPrognosisT cells

Identifiers

PMID41065822
PMCPMC12511222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.